聚乙二醇干扰素α—2a注射液联合利巴韦林治疗慢性丙肝临床效果
【摘要】 目的：研究聚乙二醇干扰素α-2a注射液（派罗欣）联合利巴韦林治疗慢性丙肝临床效果。方法：选择笔者所在医院2014年1月-2016年
6月诊疗的慢性丙肝患者55例，依据随机分配的原理，将其中27例患者作为A组，实施利巴韦林联合干扰素治疗；28例患者作为B组，实施派罗欣联合利巴韦林治疗，对比分析两组患者临床疗效与不良反应。结果：A组患者临床总有效率为70.37%，B组患者临床总有效率为96.43%，A组患者临床总有效率低于B组患者，两组患者临床疗效对比差异有统计学意义（P<0.05）。A组患者药物不良反应为55.55%，B组患者药物不良反应为32.14%，A组患者药物不良反应虽高于B组患者，但差异无统计学意义（P>0.05）。结论：慢性丙肝临床治疗中，派罗欣联合利巴韦林治疗手段的运用，既可促进临床疗效的提升，又可降低患者药物不良反应，值得推广。
【关键词】 派罗欣； 利巴韦林； 慢性丙肝
doi：10.14033/j.cnki.cfmr.2018.5.001 文献标识码 A 文章编号 1674-6805（2018）05-0001-03
【Abstract】 Objective：To study the curative effect of Pegasys united Ribavirin in the treatment of chronic hepatitis C.Method：fifty-five patients with chronic hepatitis c were selected from the hospital from January 2014 to June 2016.According to the principle of random assignment，27 patients were in group A，and the treatment of Interferon and Ribavirin were performed.The 28 patients were in group B，and the treatment of Pegasys combined with Ribavirin were performed，and the clinical efficacy and adverse reactions of the two groups were compared and analyzed.Result：The clinical total effective rate was 70.37% in group A patients，group B patients clinical total effective rate was 96.43%，group A of patients clinical total effective rate was lower than that of group B patients，there was statistically significant（P<0.05）.Group A of patients with adverse drug reactions was 55.55%，group B of patients with drug adverse reaction was 32.14%，the patients of group A was significantly higher than that of group B patients of adverse drug reactions，there was no statistical significance（P>0.05）.Conclusion：In the clinical treatment of chronic hepatitis C，the application of the combination of the treatment of Pegasys and Ribavirin can promote the improvement of clinical efficacy and reduce the adverse drug reaction of patients，which is worth promoting.
【Key words】 Pegasys； Ribavirin； Chronic hepatitis C
First-author’s address：The First People’s Hospital in Honghe Prefecture，Mengzi 661199，China
丙型病毒性肝炎（viral hepatitis type C，HC）即为丙型肝炎，因组织细胞遭受丙型肝炎病毒（HCV）侵蚀而诱发的疾病，主要以血源性传播为主[1]。丙型肝炎没有显著的临床症状和体征，疾病慢性化发展趋势尤为严重，极易引起爆发性肝衰竭[2-3]。鉴于此，本研究选择2014年1月-2016年6月诊疗的慢性丙肝患者55例为研究对象，研究聚乙二醇干擾素α-2a注射液（派罗欣）联合利巴韦林治疗慢性丙肝临床效果，报道如下。
1 资料与方法
1.1 一般资料
选择笔者所在医院2014年1月-2016年6月诊疗的慢性丙肝患者55例，患者均经病理检查、临床诊断确诊为慢性丙肝，即ALT（丙氨酸氨基转移酶）指标超过标准值1.5倍，总胆红素低于17.0 mmol/L[4]。排除标准：妊娠期、哺乳期女性；短期内给予抗病毒和免疫抑制治疗患者；存在精神病史、自身免疫病史、失代偿期肝硬化史患者。患者均知情同意本研究，本研究经医院伦理委员会批准。依据随机分配的原则，将其中27例患者作为A组，28例患者作为B组。A组：男15例，女